Search Results

You are looking at 41 - 50 of 62 items for :

  • "peptide receptor radionuclide therapy (PRRT)" x
  • Refine by Access: All content x
Clear All
Free access

Ashley K Clift and Andrea Frilling

I Nicolini S Kwekkeboom DJ Krenning EP Baum RP Paganelli G 2016 Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine

Restricted access

Mirela Diana Ilie, Alexandre Vasiljevic, Emmanuel Jouanneau, and Gérald Raverot

). Currently, there is no recommended alternative to temozolomide and no recommended treatment once temozolomide has failed ( Raverot et al. 2018 ). Promising options are represented mainly by bevacizumab, peptide receptor radionuclide therapy (PRRT), and

Open access

Sara Pusceddu, Francesco Barretta, Annalisa Trama, Laura Botta, Massimo Milione, Roberto Buzzoni, Filippo De Braud, Vincenzo Mazzaferro, Ugo Pastorino, Ettore Seregni, Luigi Mariani, Gemma Gatta, Maria Di Bartolomeo, Daniela Femia, Natalie Prinzi, Jorgelina Coppa, Francesco Panzuto, Lorenzo Antonuzzo, Emilio Bajetta, Maria Pia Brizzi, Davide Campana, Laura Catena, Harry Comber, Fiona Dwane, Nicola Fazio, Antongiulio Faggiano, Dario Giuffrida, Kris Henau, Toni Ibrahim, Riccardo Marconcini, Sara Massironi, Maja Primic Žakelj, Francesca Spada, Salvatore Tafuto, Elizabeth Van Eycken, Jan Maaten Van der Zwan, Tina Žagar, Luca Giacomelli, Rosalba Miceli, and NEPscore Working Group

received by the patients during the course of the disease. However, since peptide receptor radionuclide therapy (PRRT) has been shown to prolong OS in midgut NET (interim analysis of the NETTER-1 trial) ( Strosberg et al . 2017 ), unlike other approved

Free access

Marianne E Pavel and Christine Sers

, peptide receptor radionuclide therapy (PRRT) and systemic chemotherapy. All options are established in the management of NET, but their evidence level differs for intestinal (iNET) and pancreatic NET (pNET) ( Fig. 1 ). Formerly the term ‘carcinoid’ was

Free access

David Taïeb, Abhishek Jha, Giorgio Treglia, and Karel Pacak

sensitive approach for PPGL localization and can select patients for peptide receptor radionuclide therapy (PRRT). Approximately 234 ( n  = 166, 71% patients with progressive disease) PPGL patients have been treated on compassionate grounds with PRRT and

Free access

Bristi Basu, Bhawna Sirohi, and Pippa Corrie

considered for peptide receptor radionuclide therapy (PRRT). This targeted treatment modality is intuitively attractive, but resource intensive, so availability is generally confined to specialist centres with an interest in managing NETs. Furthermore, formal

Free access

Simona Grozinsky-Glasberg, Ilan Shimon, Márta Korbonits, and Ashley B Grossman

studies are needed to understand their complex biological effects. Phase I studies are currently underway with a chimaeric SSTR/dopamine receptor agonist, dopastatin (Ipsen, Paris, France). SSTR targeted radiotherapy (peptide receptor radionuclide therapy

Open access

Emanuel Christ, Kwadwo Antwi, Melpomeni Fani, and Damian Wild

localization of the tumor is the primary goal, the clinical challenge in metastasizing insulinomas is to define the extension of disease and – if possible – offer a targeted therapy (peptide receptor radionuclide therapy; PRRT). Contrary to benign insulinomas

Open access

J Crona, F Beuschlein, K Pacak, and B Skogseid

revised approach’ ( Grocott 2017 ). In addition, this study does not consider preoperative safety that is of concern in patients with catecholamine-secreting tumors. Oncological treatment Efficacy and safety of peptide receptor radionuclide therapy

Free access

Vincenzo Marotta, Maria Chiara Zatelli, Concetta Sciammarella, Maria Rosaria Ambrosio, Marta Bondanelli, Annamaria Colao, and Antongiulio Faggiano

transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors . European Journal of Nuclear Medicine and Molecular Imaging 43 839 – 851 . (